Both GIP and GLP-1 receptors exist in brain regions controlling appetite and reward, which is why tirzepatide reduces food cravings and not just physical hunger
Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu W, Gupta N, Skye SM, Cody DB, Levison BS, et al
Suggested Use: 1 lozenge 1 to 3 times daily
Wegovy (semaglutide) is an injectable GLP-1 (glucagon-like peptide-1) medication that was initially approved by the Food and Drug Administration (FDA) for weight loss along with lifestyle changes like diet and exercise
Domperidone carries a risk of QT interval prolongation and serious cardiac arrhythmias , and is subject to prescribing restrictions
Helping individuals quit smoking by influencing reward pathways